Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | FYN | P06241 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA3 | P07451 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA6 | P23280 | 1/20 | 0.41 |
| ▸ | CA5A | P35218 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.41 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30337032 | 1.00 | LCK (0.47) | LCKFYNGAASOS1HSD17B10 | |
| SCHEMBL16869865 | 0.93 | LCK (0.51) | LCKFYNGAASOS1HSD17B10 | |
| SCHEMBL8378560 | 0.91 | GAA (0.49) | LCKFYNGAASOS1CA12 | |
| SCHEMBL2319843 | 0.87 | LCK (0.60) | LCKFYNGAASOS1HSD17B10 | |
| SCHEMBL11222239 | 0.87 | GAA (0.51) | GAAHSD17B10CA12CA1CA2 | |
| SCHEMBL29633948 | 0.87 | LCK (0.60) | LCKFYNGAASOS1HSD17B10 | |
| SCHEMBL31218239 | 0.86 | GAA (0.45) | LCKFYNGAASOS1CA12 | |
| SCHEMBL31301254 | 0.84 | GAA (0.49) | LCKFYNGAASOS1CA12 | |
| SCHEMBL6858908 | 0.83 | CA12 (0.50) | LCKFYNHSD17B10CA12CA1 | |
| SCHEMBL197110 | 0.83 | SOS1 (0.50) | LCKFYNGAASOS1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117127400-A | Mite-removing and moisture-absorbing fabric and preparation method thereof | 薛桂芹 | 2023-11-28 | — | — | CN | claimed |
| CN-119143719-A | Preparation method of LH-1801 key intermediate | 扬州市普林斯医药科技有限公司 | 2024-12-17 | — | — | CN | disclosed |
| CN-115819398-B | Key intermediate of SGLT2 inhibitor, and preparation method and application thereof | 江苏联环药业股份有限公司 | 2024-06-14 | — | — | CN | disclosed |
| CN-117127400-A | Mite-removing and moisture-absorbing fabric and preparation method thereof | 薛桂芹 | 2023-11-28 | — | — | CN | disclosed |
| CN-115819398-A | SGLT2 inhibitor key intermediate and preparation method and application thereof | 江苏联环药业股份有限公司 | 2023-03-21 | — | — | CN | disclosed |
| EP-2019679-B1 | GLUCOSE TRANSPORT INHIBITORS AND METHODS OF USE | THERACOS INC (US) | 2018-06-20 | — | — | EP | disclosed |
| EP-2019679-B1 | GLUCOSE TRANSPORT INHIBITORS AND METHODS OF USE | THERACOS INC (US) | 2018-06-20 | — | — | EP | disclosed |
| EP-2064222-B1 | BENZYLIC GLYCOSIDE DERIVATIVES AND METHODS OF USE | THERACOS INC (US) | 2014-05-07 | — | — | EP | disclosed |
| EP-2064222-B1 | BENZYLIC GLYCOSIDE DERIVATIVES AND METHODS OF USE | THERACOS INC (US) | 2014-05-07 | — | — | EP | disclosed |
| WO-2013045495-A1 | PYRANO[3,2-c][2]BENZOPYRAN-6(2H)-ONE DERIVATIVES AND USES THEREOF | PROUS INSTITUTE FOR BIOMEDICAL RESEARCH, S.A. (ES) | 2013-04-04 | — | — | WO | disclosed |
| WO-2008122014-A1 | BENZYLIC GLYCOSIDE DERIVATIVES AND METHODS OF USE | THERACOS, INC. (US) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008122014-A1 | BENZYLIC GLYCOSIDE DERIVATIVES AND METHODS OF USE | THERACOS, INC. (US) | 2008-10-09 | — | — | WO | disclosed |
| US-20080242596-A1 | BENZYLIC GLYCOSIDE DERIVATIVES AND METHODS OF USE | THERACOS, INC. (US) | 2008-10-02 | — | — | US | disclosed |
| US-20080242596-A1 | BENZYLIC GLYCOSIDE DERIVATIVES AND METHODS OF USE | THERACOS, INC. (US) | 2008-10-02 | — | — | US | disclosed |
| US-20080242596-A1 | BENZYLIC GLYCOSIDE DERIVATIVES AND METHODS OF USE | THERACOS, INC. (US) | 2008-10-02 | — | — | US | disclosed |
| WO-2007140191-A2 | GLUCOSE TRANSPORT INHIBITORS AND METHODS OF USE | THERACOS, INC. (US) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007140191-A2 | GLUCOSE TRANSPORT INHIBITORS AND METHODS OF USE | THERACOS, INC. (US) | 2007-12-06 | — | — | WO | disclosed |
| US-20070275907-A1 | GLUCOSE TRANSPORT INHIBITORS AND METHODS OF USE | SEED, BRIAN | 2007-11-29 | — | — | US | disclosed |
| US-20070275907-A1 | GLUCOSE TRANSPORT INHIBITORS AND METHODS OF USE | SEED, BRIAN | 2007-11-29 | — | — | US | disclosed |
| US-20070275907-A1 | GLUCOSE TRANSPORT INHIBITORS AND METHODS OF USE | SEED, BRIAN | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275907-A1 | GLUCOSE TRANSPORT INHIBITORS AND METHODS OF USE | SLC5A1, SLC5A2, SLC2A1 | LCK 2041/4885FYN 3050/4885GAA 223/4885 |
| US-20080242596-A1 | BENZYLIC GLYCOSIDE DERIVATIVES AND METHODS OF USE | SLC5A2, SLC5A1, SLC2A1 | LCK 3248/4885FYN 2633/4885GAA 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.